Shares of Interpace Biosciences, Inc. (NASDAQ:IDXG) have earned a consensus recommendation of “Purchase” from the six study companies that are at the moment covering the corporation, MarketBeat studies. A person exploration analyst has rated the inventory with a maintain recommendation and five have assigned a invest in recommendation to the firm. The normal 12 thirty day period price objective among brokerages that have included the stock in the past calendar year is $9.67.
A quantity of equities analysts lately issued reviews on the stock. Zacks Investment Research elevated shares of Interpace Biosciences from a “promote” ranking to a “keep” score in a investigate take note on Monday, November 30th. HC Wainwright diminished their concentrate on price tag on Interpace Biosciences from $11.00 to $10.00 and set a “buy” ranking for the corporation in a research report on Thursday, October 22nd. Last but not least, Alliance Worldwide Partners reduced their concentrate on selling price on Interpace Biosciences from $9.25 to $7.00 and established a “invest in” rating for the organization in a exploration note on Thursday, Oct 22nd.
A selection of institutional investors and hedge funds have recently designed improvements to their positions in the business. Squarepoint Ops LLC acquired a new placement in shares of Interpace Biosciences in the course of the 3rd quarter valued at around $78,000. Stonepine Money Management LLC acquired a new stake in shares of Interpace Biosciences in the 3rd quarter really worth approximately $880,000. Magnus Financial Group LLC bought a new placement in Interpace Biosciences in the course of the 3rd quarter valued at approximately $150,000. Ultimately, Virtu Monetary LLC purchased a new placement in Interpace Biosciences in the course of the 2nd quarter valued at somewhere around $55,000. Institutional buyers and hedge money possess 9.27% of the firm’s stock.
Shares of Interpace Biosciences stock opened at $3.41 on Tuesday. The business has a 50 day transferring average of $3.24 and a 200 day shifting ordinary of $4.06. Interpace Biosciences has a 52 7 days lower of $2.57 and a 52 7 days substantial of $11.00. The business has a market place cap of $13.76 million, a PE ratio of -.40 and a beta of 1.33. The business has a brief ratio of 1.62, a recent ratio of 1.62 and a debt-to-equity ratio of 2.01.
Interpace Biosciences (NASDAQ:IDXG) previous issued its quarterly earnings data on Monday, October 19th. The business products and services service provider claimed ($1.35) earnings for each share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $.13. Interpace Biosciences experienced a destructive net margin of 115.30% and a detrimental return on equity of 251.52%. The enterprise had earnings of $5.45 million for the quarter. On typical, investigation analysts anticipate that Interpace Biosciences will article -5.41 earnings per share for the present year.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic exams, bioinformatics, and pathology expert services for evaluating cancer risk in the United States. The enterprise features PancraGEN, a pancreatic cyst and pancreaticobiliary reliable lesion genomic take a look at that will help medical professionals better assess threat of pancreaticobiliary cancers employing its PathFinderTG platform and ThyGeNEXT, an oncogenic mutation panel to recognize malignant thyroid nodules.
See Also: Why do commodities make any difference?
This instantaneous news alert was produced by narrative science know-how and economic details from MarketBeat in purchase to provide visitors with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Remember to send out any inquiries or feedback about this tale to [email protected]